These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35972211)

  • 21. Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.
    Nagase H; Tamaoki J; Suzuki T; Nezu Y; Akiyama S; Cole AL; Yang S; Mu G; Katsumata M; Komatsubara M; Alfonso-Cristancho R
    Pulm Pharmacol Ther; 2022 Aug; 75():102130. PubMed ID: 35714883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience.
    Matucci A; Vivarelli E; Bormioli S; Francesca N; Chiccoli F; Valentina M; Francesca G; Oliviero R; Parronchi P; Vultaggio A
    J Asthma; 2023 Jan; 60(1):158-166. PubMed ID: 35112934
    [No Abstract]   [Full Text] [Related]  

  • 24. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
    Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
    Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
    van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
    J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
    [No Abstract]   [Full Text] [Related]  

  • 26. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
    Bel EH; Wenzel SE; Thompson PJ; Prazma CM; Keene ON; Yancey SW; Ortega HG; Pavord ID;
    N Engl J Med; 2014 Sep; 371(13):1189-97. PubMed ID: 25199060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of mepolizumab in patients with severe eosinophilic asthma: results from real-world clinical practice in Finland.
    Koistinen V; Kauppi P; Idänpään-Heikkilä J; Veijalainen L; Iso-Mustajärvi I; Ylisaukko-Oja T; Mehtälä J; Viinanen A; Kilpeläinen M
    J Asthma; 2022 Dec; 59(12):2375-2385. PubMed ID: 35094632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mepolizumab effectiveness and identification of super-responders in severe asthma.
    Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Effectiveness of IL-5/5Ra Targeted Biologics in Severe Eosinophilic Asthma With Comorbid Bronchiectasis.
    Bendien SA; Kroes JA; van Hal LHG; Braunstahl GJ; Broeders MEAC; Oud KTM; Patberg KW; Smeenk FWJM; van Veen IHPAA; Weersink EJM; Fieten KB; Hashimoto S; van Veen A; Sont JK; van Huisstede A; van de Ven MJT; Langeveld B; Maitland-van der Zee AH; Ten Brinke A;
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2724-2731.e2. PubMed ID: 37295671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
    Bravo-Gutiérrez FJ; Miralles-López JC; Valverde-Molina J; Alemany Francés ML; Andújar-Espinosa R; Castilla-Martínez M; Avilés-Inglés MJ; Mora-González A; Pajarón-Fernández MJ; Cabrejos-Perotti S; Meseguer-Arce J; Flores Martín I; Pérez-Fernández V;
    Int Arch Allergy Immunol; 2024; 185(3):253-259. PubMed ID: 38035559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
    Fyles F; Nuttall A; Joplin H; Burhan H
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
    Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
    Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma.
    d'Ancona G; Kavanagh J; Roxas C; Green L; Fernandes M; Thomson L; Dhariwal J; Nanzer AM; Jackson DJ; Kent BD
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32060061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A real-life cohort of mepolizumab treatment in severe eosinophilic asthma.
    Laorden D; Hernández I; Domínguez-Ortega J; Romero D; Álvarez-Sala R; Quirce S
    Eur Ann Allergy Clin Immunol; 2024 Jul; 56(4):169-175. PubMed ID: 36927725
    [No Abstract]   [Full Text] [Related]  

  • 36. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry.
    Thomas D; Harvey ES; McDonald VM; Stevens S; Upham JW; Katelaris CH; Kritikos V; Gillman A; Harrington J; Hew M; Bardin P; Peters M; Reynolds PN; Langton D; Baraket M; Bowden JJ; Bowler S; Chien J; Chung LP; Farah CS; Grainge C; Jenkins C; Katsoulotos GP; Lee J; Radhakrishna N; Reddel HK; Rimmer J; Sivakumaran P; Wark PAB; Gibson PG
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2715-2724.e5. PubMed ID: 33545399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma.
    Pilette C; Canonica GW; Chaudhuri R; Chupp G; Lee FE; Lee JK; Almonacid C; Welte T; Alfonso-Cristancho R; Jakes RW; Maxwell A; Price RG; Howarth P
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2646-2656. PubMed ID: 35753668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
    Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
    BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.